Prostate Cancers

Magnetic resonance-guided daily adaptive stereotactic body radiotherapy appeared associated with a reduction in acute toxicity compared with a more common technique for men with prostate cancer, according to data published in Cancer.

Long-term survivors of certain early-stage cancers diagnosed after age 65 years appeared at higher risk for mortality due to noncancer causes, according to study results published in JAMA Network Open.

Federal research funding appeared to be allocated more toward cancer types with higher incidence among white people than members of other racial and ethnic groups, according to a study published in Journal of the National Cancer Institute.

The number of cancer survivors with self-reported functional limitations throughout the United States has more than doubled over the past 2 decades, according to data published in JAMA Oncology.

In this video, Paul Nguyen, MD, a genitourinary radiation oncologist at Dana-Farber Cancer Institute, discusses the FORMULA-509 trial he co-presented at ASCO Genitourinary Cancers Symposium.

Two phase 3 trials evaluating pembrolizumab in combination with additional agents failed to meet their primary endpoints, according to the agent’s manufacturer.

In this video, Ben Tran, MD, discusses the PEACE-1 and STAMPEDE studies that looked at the addition of abiraterone acetate plus prednisolone (AAP) to standard therapy, which was found to improve survival vs. standard therapy.